GoldenGolden
Advanced Search
Artios Pharma

Artios Pharma

Artios Pharma develops cancer treatments that target DNA Damage Response (DDR) Pathways to selectively kill cancer cells

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

August 2018
Artios Pharma raises a $84,000,000 series B round from AbbVie Biotech Ventures, Andera Partners, Arix Bioscience plc, IP Group, M Ventures, Novartis Venture Fund, Pfizer Ventures and SV Health Investors.
September 21, 2016
Artios Pharma raises a $33,200,000 series A round.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Nick Paul
April 6, 2021
FierceBiotech
Novartis has struck a deal with Artios Pharma to access DNA damage response (DDR) targets with the potential to enhance its radioligand therapies. Artios, which is run by some of the people behind pioneering DDR drug Lynparza, is set to get $20 million upfront and up to $1.3 billion in milestones in return for the targets.
Artios
February 11, 2021
www.prnewswire.com:443
/PRNewswire/ -- Artios Pharma Limited ("Artios"), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the...
Ben Adams
December 3, 2020
FierceBiotech
Germany's Merck is signing up to a small upfront but potentially huge biobucks pact with U.K.-U.S. biotech Artios.
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.